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The relation between infection and reproductive outcome involves several problems regarding the 
decrement of fertility due to the inflammatory reaction in the female pelvis. Moreover another 
important issue concern the risk of transmission to the partner and to the embryo. For those reasons 
all the couple with infertility or recurrent miscarriage should be screened for hepatitis B virus 
(HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), rubella, syphilis, and 
Chlamydia IgG and IgA serology; TPHA-VDRL. It could be suggested also to test for Chlamydia 
trachomatis, Mycoplasma hominis, Ureaplasma urealyticum, and Candida albicans, a vaginal and 
endocervical microbiological samples from female and a microbiological sperm samples from the 
male. In recent years, the rate of survival and expectation of life of people with chronic infections 
disease has dramatically improved and this has leaded to an increased demand for ART (Assisted 
Reproduction Tecniques). We well know the main positive factors that contribute to successful in 
vitro fertilization (IVF) cycles are to one side maternal age, the oocytes  the number and quality of 
transferred embryos to embryoloby lab. It has become critically important that appropriate 
guidelines be adopted to handle these cases and to manage infection avoiding risk of contamination 
and infection. The purpose of this paper is to describe issues relating to infection during IVF and to 
propose guidelines to control infection and to increase laboratory safety. 
HEPATITIS B VIRUS  
From the epidemiological point of view, the prevalence of HBV infection in the general population 
is 2% in western Europe and the USA, 2-7% in eastern Europe and South America, and 7% in 
Africa and Asia. In Italy, considering the population between 40 and 60 years, 40% have positive 
markers. In all pregnant women the prevalence is 1.6%. The prevalence in reproductive-age women 
is 1-2%, but there is great risk of diffusion from the infected male: more than 50% of partners are 
infected or seropositive. Chronic infection does not seem to decrement fertility or to have adverse 
effects on pregnancy and the pregnancy does not influence the course of hepatitis B infection.HBV 
is mainly transmitted through mucosal exposure to the blood or other fluids (saliva, bile, nasal 
secretion, human milk, sperm, vaginal mucus) of infected people. Therefore, the transmission 
occurs mostly through parenteral means, by sexual intercourse, but also via saliva. This virus has a 
parenteral spread and a high infective potential even after exsiccation out of the body.  
• If, in a couple, one or both partners are positive for HBsAg, it is necessary to screen for all 
the serologic markers for hepatitis B (HBsAg, HBeAg, HBV DNA virus). The probability of 
transmission from a women to her child is 215% if she is HBsAg positive, but 80 90% if she is 
HBsAg positive and HBeAg positive or HBV DNA positive. 
•  If the woman is positive for HBsAg but all other criteria are negative and the male partner 
is negative, it is recommended that the partner be vaccinated and informed of the risks for vertical 
transmission (perinatal prophylaxis is required).  
• When the man is positive for HBsAg but all other criteria are negative, it is important for 
him to understand that he is able to transmit the infection sexually and that is relevant the woman is 
vaccinated and antibody titers (anti-HBs >10 mU/mL) requested. Furthermore, there are risks of 
infection for the operators during the sperm treatment process, so strict precautionary measures are 
necessary. 
 
   
HEPATITIS C VIRUS  
Acute HCV infection is often asymptomatic and it is rarely associated with icteric hepatitis. 
Transmission can occur by symptomatic subjects with acute or chronic hepatitis, but mostly it 
occurs via asymptomatic infected carriers with no clinical signs of infection or alterations of 
hematological markers.  Several studies evaluated HCV prevalence in the general population in 
Italy and they show many variations by zone and age (in particular, the range was 2.4% of Lazio to 
16.3% of Campania). Therefore, it is only possible to approximate the prevalence in Italy. The 
incidence is 1 in 100,000. HCV has low sexual transmission rates. In fact, the prevalence of anti-
HCV antibodies in the partners of HCV subjects is slightly above the average of the general 
population. Vertical transmission occurs in 5% of cases of high viremia. Intravenous drug use and 
association with HIV increase the risk of fetal and neonatal infection.  
It is important to suggest a  preconceptive control in the couple because it is possible to eradicate 
the woman’s infection before pregnancy (by pharmacologic treatment with interferon), the 
effectiveness of elective cesarean to reduce transmission has yet to be proved, and it is possible to 
transmit the virus via the sperm of an infected man.  
• If the woman is anti-HCV positive, we should test the virus-positive results with a RIBA or 
qualitative PCR; if plasmatic HCV-RNA is negative, there is no viremia and therefore no vertical 
transmission; if the hepatitis is chronic, generally there are no contraindications to hormonal 
administration or pregnancy. (2)  
• If the man is anti-HCV positive the dosage of viremia is less important as few cases with 
viremia have HCV-RNA in the sperm or inside the spermatozoa, but there are differences between 
the studies. French studies suggest that the presence of HCV RNA in the sperm could be an 
indication for serologic testing of the woman with an infected partner after insemination or embryo 
transfer. However, current data do not indicate that ARTs are necessary to prevent infection of a 
woman by her HCV-infected partner. (3)  
• If the woman is HCV positive, we must also evaluate RNA: if the RNA is negative, no 
problem exists; if the RNA is positive, there is a 5% risk of vertical transmission.  
Usually the disease in the newborn is chronic and benign, and there are few important cases of 
hepatitis. No case of activations of maternal hepatitis has been reported. For HCV-positive patients 
a consultation with an infectious diseases specialist is recommended and the interferon + ribavirin 
therapy is considered suitable and effective before ART (60-80% in some types of virus). This 
therapy is contraindicated during pregnancy and ART must delay 7 months after therapy. (4)  
• When the man is HCV positive, there are few data regarding fetal infection from 
spermatozoon, and the rate of sexual transmission is very low if the hepatitis is chronic (0.4 1%), it 
is important to detect the viremia by the PCR technique. It has been showed that sperm preparation 
following the Semprini protocol is effective in removing both HCV and HIV viruses and after that it 
can be suggested the most suitable ART programme.  
HUMAN IMMUNODEFICIENCY VIRUS  
HIV affects 40 million people throughout the world. In Italy, there are about 100,000 people 
infected, 33% of them are women. Of infected people, 95% are between 20 and 49 years of age 
(maximal incidence: 30.8% between 30-34 years).  
• If the woman is positive and the partner is HIV negative, the risk of HIV transmission to the 
man can be eliminated using homologous insemination with his sperm. In asymptomatic women 
whose infection is well controlled, pregnancy does not aggravate HIV disease. (14,15) 
Amniocentesis is strongly contraindicated, because of the high risk of vertical transmission  
• Untreated HIV-positive women have a risk of vertical transmission greater than 20% in 
relation to viremia, but the treatment with zidovudine during the delivery and further administration 
of zidovudine to the newborn child for 6 weeks reduce the risk to 5-8%. Delivery by cesarean 
section and no breastfeeding reduce further the risk to 2%. Optimization of antiretroviral therapy of 
the mother with viremia HIV negative (< 40 copies/mL) increases that chance of having an 
uninfected baby.  
• If the man is positive, the use of condoms during sexual intercourse, except during the 
ovulatory period, can reduce the risk of infecting the woman, but it does not eliminate it 
(seroconversionindex is 4.3%), and therefore this method is not recommended. In 1998, Semprini 
and colleaguesusing a density gradient and other techniques for washing sperm, obtained sperm 
with no measurable levels of HIV by PCR and used these washed sperm in ART techniques. To 
reduce the possibility of infection, it is always important to offer highly active antiretroviral therapy 
(HAART) which decreases the viremia of the infected partner. It is also important to remember that 
blood viral count does not always correlate with sperm viral count because the virus segregates into 
different compartments and finds some glands a better habitat than others. (16) 
• When both man and woman are positive and the viremia is reduced to “undetectable” in 
both partners (less then 40 copies/ mL), the couple can have an HIV-negative child (risk 2%). More 
aggressive anti-HIV therapies have remarkably extended life expectancy and ethics problems are 
similar to those of couples that are carriers of recessive autosomal genetic damage (25% risk) or 
with falciform anemia or cystic fibrosis who adopt a child or use donor gametes. 
CHLAMYDIA TRACHOMATIS  
C. trachomatis genital infection is a common sexually transmitted bacterial infection. Because a 
high percentage of infected subjects are asymptomatic (70% of women and 75% of men), it is 
estimated that only 10% of the infections are diagnosed. Yet, untreated infection can lead to severe 
complications, such as chronic pelvic pain, pelvic inflammatory disease, conditions related to  
ectopic pregnancies, subfertility or even infertility.  
Moreover, infection is associated with an increased risk of HIV transmission. The prevalence of 
infection depends on the characteristics of the population studied. Important risk factors are sexual 
intercourse without barrier contraceptive methods, a new partner or more than one partner, history 
of sexually transmitted diseases and being nulliparous or unmarried.  
C. trachomatis can infect both women and men, and they have different symptoms and signs. In 
women, infection causes vaginal secretions, postcoital or intermenstrual spotting bleeding or 
spotting bleeding during administration of EPO, a hyperemic and friable cervix, urethritis, pelvic 
inflammatory disease, and, in sexually active women, pelvic pain and reactive arthritis. In men, it 
causes urethritis and urethral secretion, dysuria and, in sexually active men, epididymitis- orchitis 
and reactive arthritis.  
Before starting an ART procedure or during a preconceptional counseling, it is important to 
consider the treatment of infection. Treatment should be performed only in specific cases, 
particularly in all patients with signs or symptoms associated with C. trachomatis infection (after 
diagnostic withdrawal, without laboratory test results) with particular attention to whether they are 
undergoing IVF cycles (risk of systemic dissemination during ISG, OLP, ISC, insemination) 
Treatment of an uncomplicated genital C. trachomatis infection can include 1 gr azithromycin in a 
single dose and 100 mg doxycycline twice a day for 7 days or erythromycin (2 gr/day for 7 days). 
For the treatment of genital infections involving high genitals, good tests of effectiveness are not 
available for women (salpingitis/pelvic inflammatory disease) or for men (epididymis-orchitis). 
SIGN guidelines for women recommend 100 mg doxycycline two times/day for a minimum of 10 
days, or 400 mg ofloxacin two times/day associated with 200 mg metronidazole four times/day or 
400 mg two times/day for 7 days, or 450 mg clindamycin four times/day. For men, the 
recommended treatments are 100 mg doxycycline two times/day for 7-14 days or 250 mg 
oxytetracycline four times/day for 7-14 days. The recommended treatment of mucopurulent 
cervicitis is 1 gr azithromycin in a single dose or 100 mg doxycycline two times/day for 7 days. It is 
very important to stop sexual intercourse until the end of the therapy (that means after 7 days of 
doxycycline or after 7 days from the azithromycin dose).  
Chlamydia Infection during Pregnancy  
If the genital infection by C. trachomatis occurs during pregnancy, it can produce several dangerous 
situations for the mother and the fetus. There can be intrauterine growth retardation, premature 
labor, or a low birth weight, premature rupture of the membranes, the death of the newborn, or 
postpartum endometritis. Treatment of uncomplicated C. trachomatis genital infection during 
pregnancy can be one of the following equally effective therapies: 500 mg erythromycin four 
times/day for 7 days (erythromycin estolate is contraindicated in pregnancy) or 500 mg amoxycillin 
3 times/day for 7 days. Screening could be carried out in the first trimester of pregnancy as it could 
reduce complications such as premature delivery, while in the third trimester it could prevent 
transmission of the infection to the baby.  
NEISSERIA GONORRHOEAE  
Neisseria gonorrhoeae is a gram-negative diplococcus transmitted by direct contact with urethral, 
cervical, rectal, pharyngeal, and conjunctival secretions. In rare cases (<1%), infection spreads and 
can cause cutaneous lesions, arthritis, and tenosynovitis. Oral and pharyngeal infections can be 
asymptomatic, but infection can spread to the genitals by oral intercourse. In women, the genital 
infection is asymptomatic in 50% of cases; in the other 50% it produces leukorrhea, mucopurulent 
discharge, pelvic pain, and dysuria. In men, the genital infection is asymptomatic in 10% of cases, 
and in the other 90% it produces dysuria, mucopurulent discharge, and rarely (<1%) epididymitis 
and prostatitis. In woman neisseria infection, which is often associated with Chlamydia infection, is 
a frequent cause of infertility or subfertility.  
VULVOVAGINITIS 
Vulvovaginitis is characterized by leukorrhea, vulvar itch, and irritation. The most frequent causes 
of vaginitis are thricomoniasis, aspecific bacterial vaginosis,and candidosis. In rare cases, vaginitis 
is caused by Chlamydia or Gonococcus. Candida and Trichomonas don’t usually involve high 
genital tract and they don’t usually have role in infertility or miscarriage.  
Nonspecific Bacterial Vaginosis 
Nonspecific bacterial vaginosis is a syndrome caused by ,abnormal growth of anaerobic bacteria 
(Prevotella, Mobiluncus), Gardnerella vaginalis, or Mycoplasma hominis due to the detriment of 
the peroxide-producing Lactobacilli. Half the cases are asymptomatic and it is unknown if it is 
sexually transmitted. Bacterial vaginosis could be the cause of pelvic inflammatory disease and 
endometritis after invasive procedures (e.g., endometrial biopsy, hysterectomy, HSG, intrauterine 
device insertion, curettage). Between 9to23% of pregnant women are affected by bacteriaol 
vaginosis. Some data show an association between bacterial vaginosis and preterm delivery (RR 
1.46.9), chorioamnionitis, PROM (RR 2.0 7.3), postpartum endometritis, and spontaneous 
miscarriage (RR 1.3 2.0). The  management of bacterial vaginosis depend on several factors: 
• all symptomatic women must be treated for bacterial vaginosis,  
• asymptomatic women with a low risk of preterm labor must not be screened for bacterial 
vaginosis;  
• asymptomatic women with a high risk of preterm labour should be screened for bacterial 
vaginosis during the first prenatal exam.  
Herpes 
Herpes is a recurrent infection caused by one of two herpes simplex viruses (HSV1 or HSV2). 
HSV1 causes up to 30% of the first-episode infections; HSV2 is more involved in recurrent cases. 
Clinical diagnosis is often ineffective because the typical lesions are not present (vesicles and 
ulcerations). Detection of virus in a culture is the most suitable diagnostic test in cases of active 
infection. Measurement of specific antiviral antibodies can distinguish between the two types of 
HSV and allows identification of asymptomatic infected patients. In the first clinical episode, the 
recommended treatment is oral doses of 400 mg acyclovir three times a day for 710 days or oral 
doses of 200 mg acyclovir five times a day for 7-10 days. In a recurrence, it is important to start the 
treatment within the first day of symptoms (with oral doses of 400 mg acyclovir three times a day 
for 5 days, oral doses of 200 mg acyclovir five times a day for 5 days, or oral doses of 800 mg 
acyclovir twice a day for 5 days). Long-term follow-up treatment can reduce relapses until a 3/4 
oral dose of 400 mg acyclovir twice daily can be administered. 
CONCLUSION 
Infection play an important role in the reproductive outcome. As explained in this paper, some 
infection can be involved in the determining of infertility, they may complicate pregnancy causing 
miscarriage, ectopic pregnancy or in the late pregnancy PROM amd preterm birth. Moreover in 
other cases there are the concern of transmission infection both to the partner and the embryo. In 
case the couple request the ART  a correct management of procedures is important to guarantee 
safety to child, partner, staff, and other patients in the IVF program. The ART procedures are 
usually organized into phases: (1) the diagnostic phase, intended to identify infections and other 
medical problems; (2) the procedures performed by physicians and biologists; and (3) the phase in 
which executive and structural requirements are formulated for ART laboratories and fertility 
clinics. A correct diagnosis is useful to identify and inform the infected subjects. When an infection 
is detected, it is important to evaluate the infection risk of the partner and the embryo as well as the 
subsequent risks during pregnancy. Furthermore a strategy can be put in place before conception 
that will include obstetrical measures to reduce risks. Establishing guidelines for procedures also 
protects the staff (e.g., operators, doctors, biologists) and other patients. Precautions will also 
prevent or at least reduce risks of contamination. 
 REFERENCES  
CENTERS FOR DISEASE CONTROL AND PREVENTION. 2002. Sexually Transmitted 
Diseases  Treatment Guidelines.  
COCCIA, M.E., A. BORINI, A. MASSACES & G. RAGUSA. 2002. Consensus Conference: 
infezioni e riproduzione. Cecos CIC.  
MYSHRA, L. & L.B. SEEF. 1992. Viral hepatitis, A through E, complicating pregnancy. 
Gastroenterol. Clin. North Am. 21: 873-887.  
FÉDÉRATION DES BLEFCO. 1997. Proposition d’attitude en matière de dépistage des hépatites B 
et C préalables à la tentative d’AMP intracouple. Contracept. Fertil. Sex 25: 313-324.  
NATIONAL INSTITUTES OF HEALTH. 1997.  
ALTER, M.J., D. KRUSZON-MORAN, O.V. NAINAN, et al. 1999. The prevalence of HCV 
infection in the USA, 1988 through 1994. N. Engl. J. Med 341: 556-562.  
BOTTA-FRILUND, D. 1994. Risque de transmission des virus B et C en procréation médicalement 
assistée (PMA). Contracept. Fertil. Sex. 22: 298-301.  
ZEUZEM, S., G. TEUBER, J.H. LEE, et al. 1996. Risk factors for the transmission of hepatitis C. J. 
Hepatol. 24: 3-10.  
PAWLOTSKY, J.M. 1997. Assistance médicale à la procréation et hépatites virales: la position du 
virologue. Contracept. Fertil. Sex. 25: 530-533.  
FONSECA, A.S.K., V.R. LUNGE & N. IKUTA. 1998. Prevalência de genótipos do vírus da 
hepatite C no estado do Rio Grande do Sul. News Lab. 27: 62-66.  
LEVY, R., J.C. TARDY, T. BOURLET, et al. 2000. Transmission risk of HCV in assisted 
reproductive techniques. Hum. Reprod. 15: 810-816.  
PANDOLFI PASSOS, E., T.R. SILVEIRA, C.C. SALAZAR, et al. 2002. Hepatitis C virus 
infection and assisted reproduction. Hum. Reprod. 17: 2085-2088.  
WEISSER, M., C. RUDIN, M. BATTEGAY, et al. 1998. Does pregnancy influence the course of 
HIV infection? Evidence from two large Swiss cohort studies. J. Acquir. Immune Defic. Syndr. 
Hum. Retrovirol. 17: 404-410.  
SAADA, M., J. LE CHENADEC, A. BERREBI, et al. 2000. Pregnancy and progression to AIDS: 
results of the French prospective cohorts. SEROGEST and SEROCO Study Groups. AIDS 14: 
2355-2360.  
SEMPRINI, A.E., T. PERSICO, V. THIERS, et al. 1998. Absence of HCV and detection of 
hepatitis G virus/GB virus C RNA sequences in the semen of infected men. J. Infect. Dis. 177: 848-
854.  
MANDELBROT, L., G. PEYTAVIN, G. FIRTION & R. FARINOTTI. 2001. Maternal-fetal 
transfer and amniotic fluid accumulation of lamivudine in human immunodeficiency virus-infected 
pregnant women. Am. J. Obstet. Gynecol. 184: 153-158.  
COOPER, E.R., M. CHARURAT, L. MOFENSON, et al. 2002. Women and Infants’ Transmission 
Study Group. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected 
women and prevention of perinatal HIV-1 transmission. J. Acquir. Immune Defic. Syndr. 29: 484-
494.  
ROUZIOUX, C. 1995. Prevention of maternal HIV transmission. Practical guidelines.Drugs 49: 17-
24; discussion 38-40.  
SPRIGGS, M. & T. CHARLES. 2003. Should HIV discordant couples have access to assisted 
reproductive technologies? J. Med. Ethics 29: 325-329.  
Management of Genital Chlamydia trachomatis Infection SIGN Publication No. 42 Published 
March 2000.  
WITKIN, S.S. & I.M. LINHARES. 2002. Chlamydia trachomatis in subfertile women undergoing 
uterine instrumentation: an alternative to direct microbial testing or prophylactic antibiotic 
treatment. Hum. Reprod. 17: 1938-1941.  
GAUDOIN, M., P. REKHA, A. MORRIS, et al. 1999. Bacterial vaginosis and past chlamydial 
infection are strongly and independently associated with tubal infertility but do not affect in vitro 
fertilization success rates. Fertil. Steril. 72: 730-732.  
  
 
